Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

CAR-T Digest - August 2020

20 April 2026: Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

GSK has announced that China’s NMPA has approved Blenrep in combination with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma who have received at least one prior therapy, marking an important expansion of treatment options in the 2L+ setting
This approval is supported by the phase 3 DREAMM-7 trial, where the Blenrep-based regimen (BVd) demonstrated strong clinical benefit, including nearly tripled median progression-free survival (36.6 vs 13.4 months) and a 42% reduction in risk of death compared to a daratumumab-based triplet
Importantly, Blenrep introduces a differentiated anti-BCMA mechanism of action, and stands out as the only anti-BCMA ADC approved in this setting in China, addressing a significant unmet need as multiple myeloma incidence and mortality continue to rise in the country
Building on its clinical profile, the regimen is designed for convenient outpatient administration, with a short infusion time, helping reduce treatment burden and improve accessibility for patients often managed in community settings
Overall, this approval reinforces Blenrep’s global clinical value and expanding footprint, with multiple regulatory approvals worldwide, and highlights its potential to deliver durable responses and survival benefit across diverse patient populations, including those with high-risk disease